Trial Profile

A Phase 2 Study of VB119 in Adult Subjects With Steroid-Sensitive Primary Minimal Change Disease (MCD) or Primary Focal Segmental Glomerulosclerosis (FSGS)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 24 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs VB-119 (Primary)
Indications Focal segmental glomerulosclerosis; Lipoid nephrosis
Focus Adverse reactions; Proof of concept; Therapeutic Use
Sponsors ACELYRIN; ValenzaBio

Most Recent Events

18 Apr 2024 Status changed from active, no longer recruiting to discontinued due to a change in sponsor.
15 Feb 2024 Planned End Date changed from 9 Nov 2023 to 15 Aug 2024.
11 Jan 2023 Planned End Date changed from 28 Feb 2024 to 9 Nov 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com